There’s nothing else like Adequan i.m.

LEARN MORE

Help slow the progressive damage of arthritis

Prescribing Adequan^® i.m. (polysulfated glycosaminglycan) at the first signs of degenerative joint disease (DJD) may help horses enjoy greater mobility over a lifetime.^1,2,3 DJD can affect horses of any age and gets worse if left untreated, so it’s important to educate your clients and identify and address it early to help preserve their horse’s joint health.

Make mobility a vital sign by talking to your clients about DJD.

Nothing works like
Adequan i.m.

Adequan i.m. is the only FDA-approved injectable PSGAG that is proven to actually treat DJD, not just its symptoms—and it’s still the only joint treatment of its kind. For 30 years, veterinarians, horse owners, riders and trainers have made Adequan i.m. a top choice for helping to extend a horse’s mobility span.

See how Adequan i.m. works

SHOW TRANSCRIPT

Transcript

"We strive to keep horses healthy, happy, and moving throughout every stage of life. Active horses need healthy cartilage to maintain effective joint function. In joints with degenerative joint disease, also known as osteoarthritis, the complex process of cartilage repair is unable to keep up with damage. Key components in the cartilage and synovial fluid are lost and not replaced. Increased catabolic enzymatic activity and damaged tissue create more damage and inflammation. Thinning of the synovial fluid makes it less effective as a joint lubricant. Softening and loss of cartilage structural composition lead to a loss in its ability to cushion and disperse the forces applied to the joint. Eventually, cartilage will fissure and expose bone, resulting in pain with every step.

Adequan i.m. Polysulphate glycosaminoglycan is recommended for the intramuscular treatment of non-infectious, degenerative, and/or traumatic joint dysfunction and associated lameness of the carpal and hawk joints in horses. After Adequan i.m. is administered and enters the bloodstream, it crosses the synovial membrane into the synovial fluid and enters the articular cartilage by diffusion.

Efficacy studies have shown Adequan IM inhibits the loss of key joint components prodigal glycan, collagen and hyaluronic acid. In vitro studies have shown Adequan IM inhibits catabolic enzymes which destroy these molecules. At the same time, it has been shown to enhance the activity of anabolic enzymes that help provide the valuable building blocks for cartilage repair and joints.

Together, Adequan IM helps to renew damaged cartilage. Adequan IM in efficacy studies has also been shown to decrease inflammation of the synovial membrane which is associated with the onset of osteoarthritis, and to increase hyaluronic acid levels in the synovial fluid. Hyaluronic acid is an important lubricating molecule which helps to restore joint lubrication.

Adequan IM is proven to reduce inflammation, restore joint lubrication, repair cartilage, and reverse the disease process. Keep joints moving and horses performing with Adequan IM. Start with it. Stay with it."

Here’s how Adequan i.m. was proven to work within equine joints

IMPROVES

lameness by reducing swelling associated with arthritis

RELIEVES

inflammation by restoring synovial lubrication

SUPPORTS

the production of new cartilage

INHIBITS

harmful enzymes that attack cartilage and synovial fluid

REVERSES

the disease process that leads to loss of cartilage

After just one intramuscular injection, Adequan i.m. quickly reaches the horse’s joints within 2 hours, where it goes to work fast and keeps working for up to four days to deliver relief.⁴ Hyaluronic acid (HA) levels nearly doubled at 48 hours with significant increases noted from 24 to 96 hours.⁴ The clinical significance of these results is unknown.

Follow recommended dosing for maximum benefit

When administered according to the recommended dosing Adequan i.m. not only reaches joints quickly, it also helps to protect and renew joint mobility¹ without the injection-site, blood clotting or efficacy issues of other joint treatments.³

DOSING & ADMINISTRATION

Peak levels achieved
in the joints within

2 hours

HA nearly
doubles at

48 HOURS

The clinical significance of the results is unknown.⁴

Detected in cartilage and
subchondral bone up to

96 HOURS

Adequan^® i.m. polysulfated glycosaminoglycan (PSGAG) solution 100 mg/mL

INDICATIONS

Adequan^® i.m. is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.

IMPORTANT SAFETY INFORMATION

There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan (PSGAG). Studies have not been conducted to establish safety in breeding horses. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For full prescribing information, click here.

FDA approval means you can prescribe with confidence

Adequan i.m. is an FDA-approved veterinary drug, which means it’s backed by clinical data that demonstrated it has passed each stage of the approval process and met the requirements for drug safety and efficacy. Non-approved alternatives don’t have the same requirements.

There is no generic Adequan i.m.

Adequan i.m. is unique because there is no generic version of the drug. While other products may claim to be the same as Adequan i.m., the reality is that it’s the only FDA-approved PSGAG for the intramuscular treatment of non-infectious degenerative joints disease of the carpal and hock joints in horses.

Chart explaining how FDA approved drugs are superior for clinical efficacy & safety studies, potency & purity standards, adverse events surveillance & reporting, good manufacturing practices standards, FDA review of labeling marketing & promotion, and detailed records of each batch

This is not a complete list of all products available.

“Adequan has survived the test of time. The only reason for that is its effect. It’s efficacious. It works. That’s why clients still request Adequan and that’s why I still recommend it.”

Robert P. Bosley

DVM, Equine Sports Medicine Group
Dr. Bosley is a paid consultant for American Regent Animal Health.

Talk to your clients about Adequan i.m.

Find handy, informative resources and tools to help you educate your clients about their horse’s joint health and and ways to improve DJD diagnosis and treatment.

VISIT RESOURCE LIBRARY

Keep up on treating equine arthritis with Adequan i.m.

Take advantage of free, fully accredited continuing education courses to learn how to identify, diagnose and treat degenerative joint disease.

COMPLETE CE COURSES

Stay informed on Adequan i.m.

Be the first to hear about important news and product information.

SIGN UP NOW

Kim DY, Taylor HW, Moore RM, Paulsen DB, Cho DY. Articular chondrocyte apoptosis in equine osteoarthritis. The Veterinary Journal 2003; 166: 52-57.
McIlwraith CW, Frisbie DD, Kawcak CE, van Weeren PR. Joint Disease in the Horse. St. Louis, MO: Elsevier, 2016; 33-48.
Adequan^® i.m. (polysulfated glycosaminoglycan), Package Insert. American Regent, Inc.
Burba DJ, Collier MA, DeBault LE, Hanson-Painton O, Thompson HC, Holder CL: In vivo kinetic study on uptake and distribution of intramuscular tritium-labeled polysulfated glycosaminoglycan in equine body fluid compartments and articular cartilage in an osteochondral defect model. J Equine Vet Sci 1993; 13: 696-703.

Advancing joint care for dogs & horses

For more than 30 years, veterinarians have relied on the American Regent Animal Health family of products to provide solutions that help support joint health in their patients. Our mission is to champion the long-term well-being and mobility of animals, from top athletes to family companions.

There’s nothing else like Adequan i.m.

Help slow the progressive damage of arthritis

Make mobility a vital sign by talking to your clients about DJD.

Nothing works like Adequan i.m.

See how Adequan i.m. works

Transcript

Here’s how Adequan i.m. was proven to work within equine joints

IMPROVES

RELIEVES

SUPPORTS

INHIBITS

REVERSES

Follow recommended dosing for maximum benefit

2 hours

48 HOURS

96 HOURS

INDICATIONS

IMPORTANT SAFETY INFORMATION

FDA approval means you can prescribe with confidence

There is no generic Adequan i.m.

“Adequan has survived the test of time. The only reason for that is its effect. It’s efficacious. It works. That’s why clients still request Adequan and that’s why I still recommend it.”

Robert P. Bosley

Talk to your clients about Adequan i.m.

Keep up on treating equine arthritis with Adequan i.m.

Stay informed on Adequan i.m.

Advancing joint care for dogs & horses

Nothing works like
Adequan i.m.